Anti-nuclear antibody screening using HEp-2 cells

Journal of Visualized Experiments

Volumn , Issue 88, 2014, Pages

  Buchner, Carol ^a   Bryant, Cassandra ^a   Eslami, Anna ^a   Lakos, Gabriella ^a  

^a INOVA DIAGNOSTICS INC   (United States)

Author keywords

Antinuclear antibody (ANA); Bioengineering; Dense fine speckled (DFS70); HEp 2; Indirect immunofluorescence (IIF); Issue 88; Systemic autoimmune rheumatic disease (SARD)

Indexed keywords

ANTINUCLEAR ANTIBODY;

CELL LINE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; PROCEDURES;

ANTIBODIES, ANTINUCLEAR; CELL LINE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS;

EID: 84903280975     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51211     Document Type: Article

References (16)

1. Meroni, P.L., & Schur, P.H. ANA screening: an old test with new recommendations. Ann Rheum Dis. 69(8), 1420-1422, doi:10.1136/ard.2009.127100, (2010).
2. Tan, E.M. Autoantibodies to nuclear antigens (ANA): Their immunobiology and medicine. Advances in immunology. 33, 167-240, (1982).
3. Sack, U. et al. Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann NY AcadSci. 1173, 166-173, doi:19.1111/j.1749-6632.2009.04735.x, (2009).
4. Watanabe, A. et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 50(3), 892-900, (2004).
5. Mahler, M. et al. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Revi. 11(9), 642-645, (2012).
6. Mahler, M., & Fritzler, M.J. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol. 2012, e494356, doi:10.1155/2012/494356, (2012).
7. Miyara, M. et al. Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol. 2013, e703759. doi:10.1155/2013/703759. (2013).
8. Mariz, H. et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 63(1), 191-200, doi: 10.1002/art.30084. (2011).
9. Muro, Y. et al. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus. 17(3), 171-176, doi:10.1177/0961203307086311, (2008).
10. Agmon-Levin, N. et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 73(1), 17-23, doi:10.1136/annrheumdis-2013-203863, (2014).
11. Craft, J. et al. The U2 small nuclear ribonucleoprotein particle as an autoantigen. J Clin Invest. 81(6), 1716-1724, doi:10.1172/JCI113511, (1998).
12. Salomonsson, S. et al. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum. 46(5), 1233-1241, doi: 10.1002/art.10232, (2002).
13. Miyawaki, S. et al. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatology. 32(8), 1488-1494, (2005).
14. Raijamkers, R., et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum. 50(2), 565-569, doi:10.1002/art.20056, (2004).
15. Yang, J.M. et al. Human scleroderma sera contain autoantibodies to protein components specific to the UC small nucleolar RNP complex. Arthritis Rheum. 48(1), 210-217, doi: 10.1002/art.10729, (2003).
16. Granito, A. et al. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn. 12(1), 65-74, doi:10.1586/erm.11.82, (2012).